Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 150 mg, 200 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
Latest News
Summary
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- In patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations, capmatinib demonstrated a median objective response rate (ORR) ranging from 50.7% to 68.8% in first-line treatment, outperforming chemotherapy (23.1%-27.0% ORR) and immunotherapy (33.3% ORR).
- In advanced NSCLC patients with MET amplification (METamp), capmatinib, alongside other MET inhibitors like tepotinib and savolitinib, showed promising results, particularly in patients progressing on epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), with capmatinib being recommended for METamp NSCLC.
- Across studies of MET inhibitors, capmatinib achieved a pooled ORR of 28.1% and a disease control rate (DCR) of 69.1%, with patients harboring METex14 skipping mutations showing higher 39.3% (95% confidence interval (CI), 0.296-0.522 (ORRs) (39.3%) and 77.8% (95% CI, 0.714-0.847 (DCRs) (77.8%) compared to those with MET protein overexpression or amplification.
- Capmatinib demonstrated a satisfactory safety profile, with most adverse events being mild (grade 1 to 2) in 87.2% of patients. Common grade ≥3 adverse events included lower extremity edema (3.5%), alanine aminotransferase (ALT) elevation (2.4%), and lipase elevation (2.2%).
- No specific safety concerns were highlighted for particular population types or subgroups in the reviewed studies.
- Elderly patients are more likely to have MET exon 14 (METex14) skipping NSCLC and may benefit from MET TKI therapies like capmatinib. Additionally, METex14 skipping mutations are more frequent in adenocarcinoma (2.4%) and sarcomatoid (12.0%) subtypes, while less common in squamous histology (1.3%), indicating potential benefits for these specific histology subgroups.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tabrecta (capmatinib) Prescribing Information. | 2024 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments | 2023 | Frontiers in Oncology |
| MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes | 2023 | Clinical Lung Cancer |
| MET-targeted therapies for the treatment of non-small-cell lung cancer: A systematic review and meta-analysis | 2022 | Frontiers in Oncology |
| MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review | 2022 | Molecular Diagnosis & Therapy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient | 2024 | Chinese Clinical Oncology |
| Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology | 2022 | Journal of the National Comprehensive Cancer Network |
| Canadian Consensus Recommendations on the Management of MET-Altered NSCLC | 2021 | Current Oncology |